|Articles|April 30, 2004

Biotech firm plans stock sale

Cytogen plans to sell 2.57 million shares of its common stock at $10.10 per share through a registered direct offering. The transaction is expected to net the company $24 million. Founded in 1980, Princeton, NJ-based Cytogen develops and commercializes

Cytogen plans to sell 2.57 million shares of its common stock at $10.10 per share through a registered direct offering. The transaction is expected to net the company $24 million. Founded in 1980, Princeton, NJ-based Cytogen develops and commercializes oncology products, including the pain management product Quadramet and diagnostic radiopharmaceutical Prostascint. The company has exclusive U.S. marketing rights to Combidex, an investigational MR agent designed to aid in the diagnosis of metastatic lymph nodes.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Subscribe Now!

Latest CME

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting
In-Person + Virtual Event

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

February 19, 2026

View more
43rd Annual Miami Breast Cancer Conference®
In-Person Event

43rd Annual Miami Breast Cancer Conference®

March 5-8, 2026

Register now!
19th Annual New York GU Cancers Congress™
In-Person Event

19th Annual New York GU Cancers Congress™

March 13-14, 2026

Register now!
Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies
Video

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Marina Chiara Garassino, MD; Sarah Goldberg, MD, MPH; Biagio Ricciuti, MD, PhD

View more
Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment
Video

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

Jacob Sands, MD; Anne Chiang, MD, PhD; Alissa J. Cooper, MD

View more
Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma
Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

View more
(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice
Video

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

Lauren Averett Byers, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS

View more
PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies
Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

View more